Long-term data support tildrakizumab safety, user-friendliness
Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
Dermatology Times is looking back on the top stories in dermatology from the month of April.
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
Dermatology Times is recapping our top expert interviews from the month of April.
Study findings suggest OCT’s effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements. Desai emphasized that most dermatologists…
López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.
A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.
A study found that in addition, recovery time was both quick and yielded minimal symptoms.
A decision from the FDA is expected in the second half of 2024.
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.
Alexa Hetzel, MS, PA-C, leads a discussion on the role both physician assistants and nurse practitioners play in diagnosis and management of plaque psoriasis, commenting…